Shots:
- The P-IIa EPICCURE trial evaluates safety, tolerability & exploratory efficacy of epicardial inj. of AZD8601 vs PBO in 11 patients (7 were treated with AZD8601 & 4 received PBO inj.) with stable CAD & decreased LVEF who undergoes CABG surgery. The therapy is being co-developed with Moderna
- The study met its 1EPs i.e., numerical trends were identified in 3 exploratory efficacy EPs over PBO, including an increase in LVEF & functional PROs, 7 patients treated with AZD8601 had NT-proBNP
- AZD8601 is a novel mRNA-based therapy that encodes for VEGF-A. AstraZeneca has signed an exclusive agreement with Moderna to discover & commercialize mRNA therapeutics for multiple diseases
Click here to read the full press release/ article | Ref: AstraZeneca | Image: Mint
The post AstraZeneca and Moderna Present Results of AZD8601 in P-IIa EPICCURE Trial for the Treatment of Heart Failure at AHA 2021 first appeared on PharmaShots.
